Cancer Medicine is a large open-access Wiley journal, launched in 2012, that takes research from every part of oncology, from laboratory biology to clinical trials and prevention, and also accepts papers referred from other Wiley journals. All articles are CC BY, with an article processing charge.
Cancer Medicine is a peer-reviewed, open access, interdisciplinary Wiley journal providing rapid publication of research across the cancer sciences. It considers submissions from all oncology specialties in four broad sections: clinical cancer research (trials, chemotherapy, radiation and surgical therapy, guidelines), cancer biology (molecular and cellular biology, genomics, immunology, epigenetics, carcinogenesis, drug discovery), cancer prevention (behavioural and psychosocial studies, screening, nutrition, epidemiology) and bioinformatics. Article types are original research, systematic reviews, meta-analyses, methods papers, brief communications and invited editorials and commentaries, and it also takes papers referred from other Wiley journals. All articles are published under the Creative Commons Attribution (CC BY) licence with authors retaining copyright; DOAJ records an article processing charge with waivers and anonymous peer review. Launched in 2012. Indexed in MEDLINE and deposited in PubMed Central.
One of the most cited papers Europe PMC returns for Luca Gianni at Fondazione Michelangelo, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One trial page and one treatment page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
This is what legitimate repurposing looks like: a registered dose-finding trial that reports its toxicities. It says nothing yet about whether mebendazole helps glioblastoma.
One bottleneck page and 16 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Typhoid carriage is one of the few modifiable risk factors for gallbladder cancer. In the UK it is rare, but it matters for people who grew up where typhoid is endemic and for the question of whether chronic carriers should be offered cholecystectomy.
Ferrara haematologist and CLL expert who chairs GIMEMA's Scientific Committee.
Senior medical oncologist and translational researcher who leads research at NCIS, with a long record in experimental therapeutics and head and neck cancer.
Haiko Bloemendal represents Radboudumc Centre for Oncology in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.
Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval.
Oddbjorn Straume represents Haukeland University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Norway.
Physician who is Executive Director of the NCI-designated Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem and President of its cancer service line.
One of the most cited papers Europe PMC returns for Luca Gianni at Fondazione Michelangelo, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One trial page and one treatment page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
This is what legitimate repurposing looks like: a registered dose-finding trial that reports its toxicities. It says nothing yet about whether mebendazole helps glioblastoma.
One bottleneck page and 16 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Typhoid carriage is one of the few modifiable risk factors for gallbladder cancer. In the UK it is rare, but it matters for people who grew up where typhoid is endemic and for the question of whether chronic carriers should be offered cholecystectomy.
Shares Ruben Mesa, PubMed & Europe PMC.